inclusion criteria: patient had to meet all of the following criteria to be randomized in this study. 1. patient was an adult male or female patient, aged 18 or above. 2. patient was diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr (reverse transcription-polymerase chain reaction). 3. patient with conditions meeting all of the following criteria: 1. oxygen saturation \> 94% on room air. 2. not requiring supplemental oxygen. 4. patient who had an onset of symptom no more than 7 days prior to the study drug administration. 5. patient had 1 or more of the sars-cov-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.

inclusion criteria: patient had to meet all of the following criteria to be randomized in this study. 1. patient was an adult male or female patient, aged 18 or above. 2. patient was diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr (reverse transcription-polymerase chain reaction). 3. patient with conditions meeting all of the following criteria: 1. oxygen saturation \> 94% on room air. 2. not requiring supplemental oxygen. 4. patient who had an onset of symptom no more than 7 days prior to the study drug administration. 5. patient had 1 or more of the sars-cov-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.

inclusion criteria: patient had to meet all of the following criteria to be randomized in this study. patient was an adult male or female patient, aged 18 or above. patient was diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr (reverse transcription-polymerase chain reaction). patient with conditions meeting all of the following criteria: oxygen saturation > 94% on room air. not requiring supplemental oxygen. patient who had an onset of symptom no more than 7 days prior to the study drug administration. patient had 1 or more of the sars-cov-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.

inclusion criteria: patient had to meet all of the following criteria to be randomized in this study. patient was an adult male or female patient, aged 18 or above. patient was diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr (reverse transcription-polymerase chain reaction). patient with conditions meeting all of the following criteria: oxygen saturation > 94% on room air. not requiring supplemental oxygen. patient who had an onset of symptom no more than 7 days prior to the study drug administration. patient had 1 or more of the sars-cov-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has one or more of the following(but not limited to)sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has one or more of the following(but not limited to)sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged 18 or above. 2. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. patient who has one or more of the following(but not limited to)sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged 18 or above. 2. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic testor rt-pcr. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. patient who has one or more of the following(but not limited to)sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration